Literature DB >> 24362685

Structure and function of respiratory syncytial virus surface glycoproteins.

Jason S McLellan1, William C Ray, Mark E Peeples.   

Abstract

The two major glycoproteins on the surface of the respiratory syncytial virus (RSV) virion, the attachment glycoprotein (G) and the fusion glycoprotein (F), control the initial phases of infection. G targets the ciliated cells of the airways, and F causes the virion membrane to fuse with the target cell membrane. The F protein is the major target for antiviral drug development, and both G and F glycoproteins are the antigens targeted by neutralizing antibodies induced by infection. In this chapter, we review the structure and function of the RSV surface glycoproteins, including recent X-ray crystallographic data of the F glycoprotein in its pre- and postfusion conformations, and discuss how this information informs antigen selection and vaccine development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24362685      PMCID: PMC4211642          DOI: 10.1007/978-3-642-38919-1_4

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  101 in total

1.  Thermostability of the human respiratory syncytial virus fusion protein before and after activation: implications for the membrane-fusion mechanism.

Authors:  M Begoña Ruiz-Argüello; Diana Martín; Steve A Wharton; Lesley J Calder; Steve R Martín; Olga Cano; Miguel Calero; Blanca García-Barreno; John J Skehel; José A Melero
Journal:  J Gen Virol       Date:  2004-12       Impact factor: 3.891

2.  Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy.

Authors:  Sarah A Connolly; George P Leser; Hsien-Shen Yin; Theodore S Jardetzky; Robert A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-08       Impact factor: 11.205

3.  Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.

Authors:  Liqun Zhang; Alexander Bukreyev; Catherine I Thompson; Brandy Watson; Mark E Peeples; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Authors:  Herren Wu; David S Pfarr; Syd Johnson; Yambasu A Brewah; Robert M Woods; Nita K Patel; Wendy I White; James F Young; Peter A Kiener
Journal:  J Mol Biol       Date:  2007-02-20       Impact factor: 5.469

5.  Identification and characterization of p63 (CKAP4/ERGIC-63/CLIMP-63), a surfactant protein A binding protein, on type II pneumocytes.

Authors:  Nisha Gupta; Yefim Manevich; Altaf S Kazi; Jian-Qin Tao; Aron B Fisher; Sandra R Bates
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-03-23       Impact factor: 5.464

Review 6.  Interaction between respiratory syncytial virus and glycosaminoglycans, including heparan sulfate.

Authors:  Louay K Hallak; Steven A Kwilas; Mark E Peeples
Journal:  Methods Mol Biol       Date:  2007

7.  Contribution of cysteine residues in the extracellular domain of the F protein of human respiratory syncytial virus to its function.

Authors:  Nicole D Day; Patrick J Branigan; Changbao Liu; Lester L Gutshall; Jianquan Luo; José A Melero; Robert T Sarisky; Alfred M Del Vecchio
Journal:  Virol J       Date:  2006-05-24       Impact factor: 4.099

8.  Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.

Authors:  Hsien-Sheng Yin; Xiaolin Wen; Reay G Paterson; Robert A Lamb; Theodore S Jardetzky
Journal:  Nature       Date:  2006-01-05       Impact factor: 49.962

Review 9.  Functional analysis of the N-linked glycans within the fusion protein of respiratory syncytial virus.

Authors:  Ping Li; Helen W McL Rixon; Gaie Brown; Richard J Sugrue
Journal:  Methods Mol Biol       Date:  2007

10.  Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps.

Authors:  Nicola Ternette; Daniela Stefanou; Seraphin Kuate; Klaus Uberla; Thomas Grunwald
Journal:  Virol J       Date:  2007-06-05       Impact factor: 4.099

View more
  102 in total

1.  Native immunogold labeling of cell surface proteins and viral glycoproteins for cryo-electron microscopy and cryo-electron tomography applications.

Authors:  Hong Yi; Joshua D Strauss; Zunlong Ke; Eric Alonas; Rebecca S Dillard; Cheri M Hampton; Kristen M Lamb; Jason E Hammonds; Philip J Santangelo; Paul W Spearman; Elizabeth R Wright
Journal:  J Histochem Cytochem       Date:  2015-06-11       Impact factor: 2.479

2.  Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors.

Authors:  Song Feng; Di Hong; Baoxia Wang; Xiufang Zheng; Kun Miao; Lisha Wang; Hongying Yun; Lu Gao; Shuhai Zhao; Hong C Shen
Journal:  ACS Med Chem Lett       Date:  2015-01-25       Impact factor: 4.345

Review 3.  Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.

Authors:  Jason S McLellan
Journal:  Curr Opin Virol       Date:  2015-03-26       Impact factor: 7.090

Review 4.  Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.

Authors:  Christopher C Stobart; Martin L Moore
Journal:  Expert Rev Vaccines       Date:  2015-10-05       Impact factor: 5.217

5.  Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.

Authors:  Stanislav O Fedechkin; Natasha L George; Ana M Nuñez Castrejon; Joshua R Dillen; Lawrence M Kauvar; Rebecca M DuBois
Journal:  J Virol       Date:  2020-02-28       Impact factor: 5.103

6.  The Heptad Repeat C Domain of the Respiratory Syncytial Virus Fusion Protein Plays a Key Role in Membrane Fusion.

Authors:  Imogen M Bermingham; Keith J Chappell; Daniel Watterson; Paul R Young
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

Review 7.  Neutralizing epitopes of RSV and palivizumab resistance in Japan.

Authors:  Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2017-09-01

Review 8.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Functional correlations of respiratory syncytial virus proteins to intrinsic disorder.

Authors:  Jillian N Whelan; Krishna D Reddy; Vladimir N Uversky; Michael N Teng
Journal:  Mol Biosyst       Date:  2016-04-26

10.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.